This is the authors' abstract. We don't add key points for this paper.
Owing to high global prevalence, incidence and associated mortality, cancer of head and neck particularly oral cancer remains a cardinal domain for research and trials. Immune-modulatory therapies that employ patients own immune system for therapeutic benefits in oral cancer seems promising. The aim of this review is to gauge the potential of immunotherapy as fourth domain of Oral cancer therapeutics. Articles were searched using suitable search terms in MEDLINE and Google Scholar database to include clinical trials, meta-analyses, and research in humans / animals/ cell lines published in peer reviewed journals. A total of 97 articles were included in this review. Literature has several studies and trials where different types of immune therapy has been attempted but it is crucial to identify precise biomarkers of genome based targeted agents and to find parameters to select patients who might benefit from immunotherapy. Also, further research is required to estimate predictive value of tumor mutational burden and mutational signatures so as to aid in personalized prediction of oral cancer therapeutic response.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Shalini Gupta (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: